These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 1838848)
1. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system. Cavero I; Pratz J; Mondot S Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848 [TBL] [Abstract][Full Text] [Related]
2. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. Borg C; Mondot S; Mestre M; Cavero I J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478 [TBL] [Abstract][Full Text] [Related]
3. The contribution of guanylate cyclase stimulation and K+ channel opening to nicorandil-induced vasorelaxation depends on the conduit vessel and on the nature of the spasmogen. Magnon M; Durand I; Cavero I J Pharmacol Exp Ther; 1994 Mar; 268(3):1411-8. PubMed ID: 7908056 [TBL] [Abstract][Full Text] [Related]
4. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo. Kamijo T; Iwai T; Haruta K; Takeda K Arch Int Pharmacodyn Ther; 1996; 331(3):273-84. PubMed ID: 9124999 [TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151 [TBL] [Abstract][Full Text] [Related]
6. Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery. Fujiwara T; Angus JA Br J Pharmacol; 1996 Dec; 119(8):1549-56. PubMed ID: 8982500 [TBL] [Abstract][Full Text] [Related]
7. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. Cavero I; Mondot S; Mestre M J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353 [TBL] [Abstract][Full Text] [Related]
8. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent. Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137 [TBL] [Abstract][Full Text] [Related]
9. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries. Nielsen-Kudsk JE Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816 [TBL] [Abstract][Full Text] [Related]
10. Analysis of cromakalim-, pinacidil-, and nicorandil-induced relaxation of the 5-hydroxytryptamine precontracted rat isolated basilar artery. Ksoll E; Parsons AA; Mackert JR; Schilling L; Wahl M Naunyn Schmiedebergs Arch Pharmacol; 1991 Apr; 343(4):377-83. PubMed ID: 1830131 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. Quast U; Cook NS J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478 [TBL] [Abstract][Full Text] [Related]
12. Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner. Satoh K; Mori T; Yamada H; Taira N Cardiovasc Drugs Ther; 1993 Aug; 7(4):691-9. PubMed ID: 8241013 [TBL] [Abstract][Full Text] [Related]
14. The dualistic mode of action of the vasodilator drug, nicorandil, differentiated by glibenclamide in 86Rb flux studies in rabbit isolated vascular smooth muscle. Kreye VA; Lenz T; Theiss U Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):70-5. PubMed ID: 1827659 [TBL] [Abstract][Full Text] [Related]
15. Role of K+ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways. Pérez-Vizcaíno F; Cogolludo AL; Villamor E; Tamargo J Br J Pharmacol; 1998 Mar; 123(5):847-54. PubMed ID: 9535012 [TBL] [Abstract][Full Text] [Related]
16. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries. Satoh K; Yamada H; Taira N Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):76-82. PubMed ID: 1827660 [TBL] [Abstract][Full Text] [Related]
17. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. Pratz J; Mondot S; Montier F; Cavero I J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538 [TBL] [Abstract][Full Text] [Related]
18. Effects of nicorandil on cytosolic calcium concentrations and on tension development in the rabbit femoral artery. Abe S; Nishimura J; Nakamura M; Kanaide H J Pharmacol Exp Ther; 1994 Feb; 268(2):762-71. PubMed ID: 8113988 [TBL] [Abstract][Full Text] [Related]
19. The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers. McPherson GA; Stork AP Br J Pharmacol; 1992 Jan; 105(1):51-8. PubMed ID: 1534504 [TBL] [Abstract][Full Text] [Related]
20. Potassium channel opening properties of a novel compound, NIP-121, cromakalim and nicorandil in rat aorta and portal vein. Masuda Y; Arakawa C; Yamashita T; Miyajima M; Shigenobu K; Kasuya Y; Tanaka S Eur J Pharmacol; 1991 Apr; 195(3):323-31. PubMed ID: 1831135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]